Skip to Content

GoNitro Approval History

GoNitro (nitroglycerin) is a nitrate vasodilator indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease.

GoNitro was approved by the FDA via the 505(b) regulatory pathway using previously reported safety and efficacy data. Clinical data demonstrated that the sublingual absorption of nitroglycerin was higher following the administration of GoNitro compared to Nitrolingual Pumpspray (nitroglycerin lingual spray).

GoNitro is supplied as single dose packets of crystal granules which are placed under the tongue at the onset of an angina attack. The most common side effects include headache, dizzinesss and paresthesia.

Development History and FDA Approval Process for GoNitro

DateArticle
Jun 14, 2016Approval Espero Pharmaceuticals Receives FDA Approval for GoNitro (nitroglycerin) Sublingual Powder

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide